Dupixent (dupilumab) is a biologic medication used to treat atopic dermatitis, asthma, and other inflammatory conditions. It works by targeting specific immune pathways involved in allergic inflammation. For many patients with moderate to severe eczema, Dupixent has provided relief where topical medications failed. As a result, it has become one of the most widely prescribed biologic drugs for skin and respiratory conditions.
But for a growing number of patients, the experience with Dupixent has been very different. Over the past several years, doctors and researchers have reported cases in which patients treated with Dupixent were later diagnosed with cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma that primarily affects the skin. These reports have led to increasing scrutiny of whether Dupixent can worsen, accelerate, or mask CTCL in certain patients.
Lawyers across the country are now reviewing Dupixent lawsuits on behalf of patients who developed CTCL, mycosis fungoides, or Sézary syndrome after receiving Dupixent injections.